SCHEMBL2307404

SCHEMBL2307404

CC(=O)OCC(=O)N1CCN(c2ccc(OCc3ccccc3)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.62
ME2 P23368 2/20 0.61
ME1 P48163 2/20 0.61
ME3 Q16798 2/20 0.61
GRM5 P41594 3/20 0.60
MAPT P10636 8/20 0.60
KDM4E B2RXH2 3/20 0.60
ALDH1A1 P00352 4/20 0.58
TP53 P04637 1/20 0.58
NPSR1 Q6W5P4 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.53
NPC1 O15118 1/20 0.53
GAA P10253 1/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
LMNA P02545 2/20 0.52
ENPP2 Q13822 1/20 0.51
HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2312575 0.87 ME2 (0.64) MAPK1ME2ME1ME3GRM5
SCHEMBL12206749 0.85 MAPT (0.77) MAPK1ME2ME1ME3GRM5
SCHEMBL945189 0.83 ME2 (0.60) MAPK1ME2ME1ME3GRM5
Hydrochloric Acid SCHEMBL2309495 0.82 ME2 (0.58) MAPK1ME2ME1ME3GRM5
SCHEMBL13465512 0.81 MAPT (0.54) MAPK1ME2ME1ME3GRM5
SCHEMBL2313406 0.80 MAPT (0.58) MAPK1ME2ME1ME3MAPT
SCHEMBL12206667 0.79 ME2 (0.61) MAPK1ME2ME1ME3GRM5
SCHEMBL12206779 0.79 MAPT (0.54) MAPK1ME2ME1ME3GRM5
SCHEMBL2314529 0.79 MAPT (0.54) MAPK1ME2ME1ME3GRM5
SCHEMBL2310298 0.79 MAPT (0.54) MAPK1ME2ME1ME3GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110250135-A1 Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-10-13 US disclosed
US-20110250135-A1 Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-10-13 US disclosed
US-20110250135-A1 Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-10-13 US disclosed
CN-102149681-A Piperazine derivatives for binding and imaging amyloid plaques and their use BAYER SCHERING PHARMA AG 2011-08-10 CN disclosed
EP-2350000-A1 PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE Bayer Schering Pharma Aktiengesellschaft (DE) 2011-08-03 EP disclosed
WO-2010028776-A1 PIPERAZINE DERIVATIVES FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110250135-A1 Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their Use APP, APBA1, PSEN1 MAPK1 3479/4885ME2 4546/4885ME1 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.